Mahmoud Reza Kalantari; Tayyebeh Nazeran; Fatemeh Varshoee Tabrizi
Volume 7, Issue 3 , July 2012, , Pages 157-164
Abstract
Background and Aims: P504S (AMACR) is a mitochondrial enzyme expressed in renal cell carcinoma. Some of immunohistochemical markers in renal cell tumors are independent prognostic factor and show relation with histologic grading. AMACR expression increases with higher histological grading in different ...
Read More
Background and Aims: P504S (AMACR) is a mitochondrial enzyme expressed in renal cell carcinoma. Some of immunohistochemical markers in renal cell tumors are independent prognostic factor and show relation with histologic grading. AMACR expression increases with higher histological grading in different tumors; however, in RCC it is not obvious. In this study, we tried to investigate if any relation existed between nuclear grading in renal cell carcinoma and P504S.
Materials & Methods: Fort five cases of formalin fixed paraffin embedded tissue of renal cell carcinoma with different nuclear grades were selected and immunostained using primary antibody to P504s and quantified with H-Score, multiplicative (Mqs) and Additive quick score (Aqs).
Results: P504S was positive in 37 out of 45 (82%) cases. (Mean ± SD) of H-Score: grade I =182±44. II=218±161, III=215±55, IV=190. Mean ± SD of Add quick score: grade I= 6.6± 1.8, II= 7.24±1.4, III= 7.78±1.2, IV= 8. Mean ± SD of Multi quick score: grade I= 9± 5.6, II= 11.38±5, III =12.89±4.7, IV= 12. (Aqs Vs H- Score: r = 0.701, P < 0.007), (Mqs Vs H-Score: r = 0.808, P < 0.001)
Conclusion: P504S is one of the important immunohistochemical markers in primary and metastatic RCC. Our results show that there is no statistically correlation between histological grade of RCC and AMACR staining in semi – quantitative measurement. We suggest AMACR staining to be used as a diagnostic immunohistochemical marker in conjunction with other markers in differential diagnosis of metastatic renal papillary and even clear cell carcinoma.
Kazem Anvari; Abdolazim Sedighi Pashaki; Mahmoud Reza Kalantari; Mehdi Seilanian Toosi; Mohammad Reza Ghavam Nasiri; Hamid Reza Raziee
Volume 4, Issue 1 , January 2009, , Pages 32-37
Abstract
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study ...
Read More
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens were stained with immunohistochemistery method for Bax and Bcl2. The relationship between Bax/Bcl2 expression and the response to chemotherapy as well as some other prognostic factors were assessed. Results: Out of 44 patients, 29 were Bax+ and 15 Bax-, 31 Bcl2+ and 13 Bcl2-. We found a statistically significant relationship between IPI score and the response to chemotherapy (P = 0.002). The response rates were relatively better (but not significant) in cases with Bax + compared to Bax – and in patients with Bcl2- compared to Bcl2 + tumors. The combination of immunohistochemistery results for Bcl2 and Bax could predict relatively higher response rates in a way that those with Bax+ Bcl2- had a higher response compared to Bax- Bcl2+ ( 57%% VS.22%, p=0.15). Conclusion: Although we found a relatively higher responses in our cases with Bax + vs. Bax - and in those with Bcl2- vs. Bcl2 +, the differences were not statistically significant. We suggest further studies to confirm whether the Bcl2 and Bax expressions have any effect on the response to chemotherapy and whether they could be considered as predictor factors for chemotherapy response.